Enhanced expression of PD-1, PD-L1, PD-L2, CTLA-4, and other immune checkpoints after HMA treatment potentially contributes to an immunosuppressive bone marrow/peripheral environment in MDS patients (15, 33). This evidence concerns the gene PDCD1LG2 and myelodysplastic syndrome.